CClinicalTrials.gg
TerminatedNCT03215667Updated Jan 25, 2021Results posted

Ridge Preservation With Moldable Beta-tricalcium Phosphate Bone Substitute on Non-containable Non-Molar Extraction Sites

An interventional study of easy-graft CLASSIC (beta-Tricalcium Phosphate) in Alveolar Ridge Preservation and Dental Implants, sponsored by Sunstar Americas. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-25.

Sponsored by Sunstar Americas · Not applicable, Interventional, and Treatment

Why this study was terminated
Insufficient recruitment
Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Purpose of the single arm study is to clinically and histologically evaluate alloplastic in-situ hardening, moldable beta-tricalcium phosphate(TCP) bone graft material and polylactide membrane in alveolar ridge preservation following extraction of non-molar teeth with non-containable extraction sockets.

02

Conditions studied

  • Alveolar Ridge Preservation
  • Dental Implants
03

In context

Lead sponsor

Sunstar Americas is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • adequate restorative space for a dental implant restoration, if the subject decides previous to study participation that they would like an implant. Note, agreement to implant placement is not a requirement of the study
  • minimum of 10-mm vertical bone without impinging on adjacent vital structures (Maxillary sinus, neurovascular bundles)
  • single-rooted tooth to be extracted
  • American Society of Anesthesiologists (ASA) Physical Status Classification I or II
  • age >18 years old
  • subjects who had >50% of height on any portion on the buccal wall of dehiscence and/or fenestration of the extraction socket following extraction will be included from this study
  • adjacent teeth to extraction site will be present during healing period
  • willingly sign informed consent and authorization.

Exclusion criteria

Exclusion Criteria:

  • do not meet any inclusion criteria
  • pregnancy or nursing woman
  • subjects with active systemic or localized infection (exclude chronic periodontitis)
  • subjects with a history of any medical conditions that contraindicated or weighed against dental implant placement such as history of bisphosphonate drug use, chemotherapeutic or immunosuppressive agents, autoimmune disease, or poorly controlled diabetes (HBA1c>7%)
  • subjects with smoking habit (more than 10 cigarettes per day)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Device treatment

    easy-graft CLASSIC (beta-Tricalcium Phosphate) grafting covered with polylactide membrane

    Device: easy-graft CLASSIC (beta-Tricalcium Phosphate)

Interventions

  • Deviceeasy-graft CLASSIC (beta-Tricalcium Phosphate)

    easy-graft will be grafted to a single extraction socket and covered by polylactide membrane to facilitate regeneration of new bone in order to preserve alveolar ridge dimensions.

    Also known as: GUIDOR Bioresorbable Matrix Barrier

06

What researchers measure

Primary outcomes

  1. Change in Radiographic Measurements of Bone Ridge Dimensions

    Cone-beam computed tomography (CBCT) was taken at the ridge preservation procedure (baseline) and 3 months after the procedure. The horizontal ridge width was measured at 1, 3, 5 and 7 mm below the alveolar bone crest. Overall change is the average of all measurements.

    Time frame: Change from Baseline at 3 months

Secondary outcomes

  1. Change in Digital Measurements of Soft Tissue Dimensions

    Pre- and post-surgery casts were made from impressions and scanned with a digital scanner. The soft tissue width was measured at 1, 3 and 5 mm below the ridge crest. Overall change is the average of all measurements.

    Time frame: Change from baseline at 5 months

07

Results

Posted Jan 25, 2021

Participant flow

Participant flow — Overall Study
MilestoneDevice Treatment
Started9
Completed5
Not completed4
Withdrew: Physician decision4

Outcome measures

PrimaryChange in Radiographic Measurements of Bone Ridge Dimensions

Cone-beam computed tomography (CBCT) was taken at the ridge preservation procedure (baseline) and 3 months after the procedure. The horizontal ridge width was measured at 1, 3, 5 and 7 mm below the alveolar bone crest. Overall change is the average of all measurements.

Time frame:
Change from Baseline at 3 months
Reported as:
Mean · mm
Change in Radiographic Measurements of Bone Ridge Dimensions
mmDevice Treatment
Overall1.59 ± 1.05
1 mm below the alveolar bone crest1.89 ± 1.03
SecondaryChange in Digital Measurements of Soft Tissue Dimensions

Pre- and post-surgery casts were made from impressions and scanned with a digital scanner. The soft tissue width was measured at 1, 3 and 5 mm below the ridge crest. Overall change is the average of all measurements.

Time frame:
Change from baseline at 5 months
Reported as:
Mean · mm
Change in Digital Measurements of Soft Tissue Dimensions
mmDevice Treatment
Overall0.99 ± 2.18
1mm below the ridge crest2.57 ± 1.35

Adverse events

Collected over 5 months after ridge preservation surgery. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Device Treatment0/9 (0%)0/9 (0%)0/9 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Device Treatment
Mean58.6 ± 15.3
Sex: Female, Male
Sex: Female, Male(Participants)Device Treatment
Female6
Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Device Treatment
Hispanic or Latino0
Not Hispanic or Latino9
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Device Treatment
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White7
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Indiana University School of Dentistry
    Indianapolis, Indiana 46202, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Jun 29, 2017

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03215667
Lead sponsor
Sunstar Americas
Responsible party
Sponsor
First posted
Jul 12, 2017
Start date
Aug 1, 2017
Primary completion
Nov 3, 2019
Completion
Nov 3, 2019
Results posted
Jan 25, 2021
Last update
Jan 25, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion